KOS-2187, a novel erythromycin-based motilin agonist, or motilide, as a clinical candidate for the treatment of gastrointestinal motility disorders such as gastroparesis and gastroesophageal reflux disease (GERD).
- Mechanism
- Curator reviewed
KOS-2187 is a potent, selective motilin receptor agonist that is chemically stable and orally bioavailable and lacks antibiotic activity. In preclinical studies, KOS-2187 showed an improved safety profile relative to erythromycin and accelerated gastric emptying, suggesting that it may provide symptom relief in several gastrointestinal diseases
- Primary indication
- Investigated for use/treatment in gastroesophageal reflux disease (GERD) and gastrointestinal diseases and disorders (miscellaneous).Curator reviewed
- Formula / weight
- C43H73NO13 · 812.051 g/mol (avg)
- Also known as
- (3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-7,10,12,13-tetrahydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl)oxy-6-[3-hydroxy-6-methyl-4-[methyl(propan-2-yl)amino]oxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-14-phenyl-oxacyclotetradecan-2-one
- Code names
- KOS-2187
Resolves to
BCKWPVFDVOGCTM-UHFFFAOYSA-NSMILESCOC1(C)CC(OC2C(C)C(OC3OC(C)CC(C3O)N(C)C(C)C)C(C)(O)CC(C)C(O)C(C)C(O)C(C)(O)C(OC(=O)C2C)C2=CC=CC=C2)OC(C)C1OWhat you can answer from here — as of April 02, 2025
Which drugs share a target with KOS-2187, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account